<!-- templates/post_template.html (1/1) - COMPLETE -->
<!DOCTYPE html>
<html lang="en">
<head>
    <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-WSLDZ2QB');</script>
    <!-- End Google Tag Manager -->

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

    <!-- *** CORE SEO & Page Info *** -->
    <title>ABS-101 Breakthrough: First AI-Designed Drug Trial for IBD Begins Human Testing - Dacoola</title>
    <meta name="description" content="Absci&#39;s AI-designed drug ABS-101 enters Phase I human trials for IBD, marking a milestone in generative AI drug development. Learn about its potential impact.">
    <meta name="author" content="AI News Team">
    

    <!-- *** CANONICAL URL *** -->
    <link rel="canonical" href="https://dacoolaa.netlify.app/articles/abs-101-breakthrough-first-ai-designed-drug-trial-for-ibd-begins-human-testing.html">

    <!-- *** OPEN GRAPH *** -->
    <meta property="og:title" content="ABS-101 Breakthrough: First AI-Designed Drug Trial for IBD Begins Human Testing">
    <meta property="og:description" content="Absci&#39;s AI-designed drug ABS-101 enters Phase I human trials for IBD, marking a milestone in generative AI drug development. Learn about its potential impact.">
    <meta property="og:image" content="https://www.zdnet.com/a/img/resize/f4bdc4720e42d9d419119c6d7162c871a8e837d2/2025/05/13/f14c8bb7-bf23-4f0e-ae91-34af5d2f0baa/gettyimages-1374389013.jpg?auto=webp&amp;fit=crop&amp;height=675&amp;width=1200">
    <meta property="og:url" content="https://dacoolaa.netlify.app/articles/abs-101-breakthrough-first-ai-designed-drug-trial-for-ibd-begins-human-testing.html">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Dacoola">
    
    <meta property="article:published_time" content="2025-05-13T21:54:06Z">
    <meta property="article:modified_time" content="2025-05-13T21:54:06Z">
    
    
    <meta property="article:tag" content="Absci generative AI therapy">
    
    <meta property="article:tag" content="Sean McClain Absci interview">
    
    <meta property="article:tag" content="irritable bowel disease AI treatment">
    
    <meta property="article:tag" content="AI-designed drug trial">
    
    <meta property="article:tag" content="Absci ABS-101 clinical trial">
    
    <meta property="article:tag" content="FDA approval for AI-designed drugs">
    
    <meta property="article:tag" content="generative AI drug development">
    
    <meta property="article:tag" content="AI in drug development process">
    
    <meta property="article:tag" content="AI drug discovery milestones">
    
    <meta property="article:tag" content="Phase I trial for AI-designed drug">
    
    <meta property="article:tag" content="AI-designed drug for IBD">
    
    <meta property="article:tag" content="first AI-designed drug human trial">
    

    <!-- *** TWITTER CARD *** -->
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="ABS-101 Breakthrough: First AI-Designed Drug Trial for IBD Begins Human Testing">
    <meta name="twitter:description" content="Absci&#39;s AI-designed drug ABS-101 enters Phase I human trials for IBD, marking a milestone in generative AI drug development. Learn about its potential impact.">
    <meta name="twitter:image" content="https://www.zdnet.com/a/img/resize/f4bdc4720e42d9d419119c6d7162c871a8e837d2/2025/05/13/f14c8bb7-bf23-4f0e-ae91-34af5d2f0baa/gettyimages-1374389013.jpg?auto=webp&amp;fit=crop&amp;height=675&amp;width=1200">

    <!-- *** Stylesheets & Icons *** -->
    <link rel="stylesheet" href="../css/styles.css"> <!-- Relative path from articles/ to public/css/ -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.2/css/all.min.css" integrity="sha512-SnH5WK+bZxgPHs44uWIX+LLJAJ9/2PkPKZ5QiAj6Ta86w+fsb2TkcmfRyVX3pBnMFcV7oQPJkl9QevSCWr3W6A==" crossorigin="anonymous" referrerpolicy="no-referrer" />
    <link rel="icon" type="image/png" href="https://i.ibb.co/W7xMqdT/dacoola-image-logo.png"> 

    <!-- *** JSON-LD Structured Data *** -->
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "NewsArticle",
      "headline": "ABS-101 Breakthrough: First AI-Designed Drug Trial for IBD Begins Human Testing",
      "description": "Absci&#39;s AI-designed drug ABS-101 enters Phase I human trials for IBD, marking a milestone in generative AI drug development. Learn about its potential impact.",
      "keywords": ["Absci generative AI therapy", "Sean McClain Absci interview", "irritable bowel disease AI treatment", "AI-designed drug trial", "Absci ABS-101 clinical trial", "FDA approval for AI-designed drugs", "generative AI drug development", "AI in drug development process", "AI drug discovery milestones", "Phase I trial for AI-designed drug", "AI-designed drug for IBD", "first AI-designed drug human trial"],
      "mainEntityOfPage": { "@type": "WebPage", "@id": "https://dacoolaa.netlify.app/articles/abs-101-breakthrough-first-ai-designed-drug-trial-for-ibd-begins-human-testing.html" },
      "image": [
        {
          "@type": "ImageObject",
          "url": "https://www.zdnet.com/a/img/resize/f4bdc4720e42d9d419119c6d7162c871a8e837d2/2025/05/13/f14c8bb7-bf23-4f0e-ae91-34af5d2f0baa/gettyimages-1374389013.jpg?auto=webp&amp;fit=crop&amp;height=675&amp;width=1200"
        }
      ],
      "datePublished": "2025-05-13T21:54:06Z",
      "dateModified": "2025-05-13T21:54:06Z",
      "author": { "@type": "Person", "name": "AI News Team" },
      "publisher": {
        "@type": "Organization",
        "name": "Dacoola",
        "logo": { "@type": "ImageObject", "url": "https://dacoolaa.netlify.app" }
      }
    }
    </script>

    <!-- Google Analytics (gtag.js) -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-WGJ5MFBC6X"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());
      gtag('config', 'G-WGJ5MFBC6X');
    </script>

</head>
<body>
    <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WSLDZ2QB"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <header id="navbar-placeholder">
        <!-- Navbar loaded by JS -->
    </header>

    <div class="site-content-wrapper">
        <div class="main-content-grid">

            <aside class="sidebar related-news">
                <h2>Related News</h2>
                <div id="related-news-content">
                    <!-- JS will populate this list with article cards -->
                    <p class="placeholder">Loading related news...</p>
                </div>
            </aside>

            <article class="main-article"
                data-article-id="7c7c41dc1f5b7cd8a66da79acab83c2f52bbf355a91254f5e7b02ff7f4ee4875"
                data-article-topic="Health"
                data-article-tags='["Absci generative AI therapy", "Sean McClain Absci interview", "irritable bowel disease AI treatment", "AI-designed drug trial", "Absci ABS-101 clinical trial", "FDA approval for AI-designed drugs", "generative AI drug development", "AI in drug development process", "AI drug discovery milestones", "Phase I trial for AI-designed drug", "AI-designed drug for IBD", "first AI-designed drug human trial"]'
                data-audio-url="">

                <header>
                    <h1 id="article-headline">ABS-101 Breakthrough: First AI-Designed Drug Trial for IBD Begins Human Testing</h1>
                    <div class="article-meta-container">
                        <div class="article-meta">
                            Published on <span id="publish-date">May 13, 2025</span>
                            by <span id="author-name">AI News Team</span>
                            
                            <span class="article-source-inline">
                                  |   <a href="https://www.zdnet.com/article/this-ai-designed-drug-for-ibd-was-just-given-to-human-subjects-for-the-first-time/" target="_blank" rel="noopener noreferrer" class="article-source-inline-link" title="View original source article">View Original Source</a>
                            </span>
                            
                        </div>
                        <!-- Any other meta items can go here, e.g., reading time if you calculate it -->
                    </div>
                </header>

                
                <figure class="article-image-container">
                    <img id="article-image" src="https://www.zdnet.com/a/img/resize/f4bdc4720e42d9d419119c6d7162c871a8e837d2/2025/05/13/f14c8bb7-bf23-4f0e-ae91-34af5d2f0baa/gettyimages-1374389013.jpg?auto=webp&amp;fit=crop&amp;height=675&amp;width=1200" alt="ABS-101 Breakthrough: First AI-Designed Drug Trial for IBD Begins Human Testing">
                </figure>
                

                <section id="article-body">
                    <h2>ABS-101 Breakthrough: First AI-Designed Drug Trial for IBD Begins Human Testing</h2>
<p>In a landmark moment for AI-driven medicine, Absci’s ABS-101-the first fully AI-designed drug for irritable bowel disease (IBD)-has entered Phase I human trials. The Vancouver-based biotech startup announced the dosing of healthy volunteers, a critical step toward potential FDA approval. This AI-designed drug trial represents a significant leap in reducing development time and costs, with ABS-101 reaching clinical stages in just 24 months at a fraction of traditional expenses.  </p>
<h3>A New Era for AI in Drug Development</h3>
<p>Absci’s generative AI platform designed ABS-101 from scratch, targeting the TL1A protein linked to inflammatory autoimmune diseases. Unlike conventional methods, which rely on animal immune systems to generate antibodies, Absci’s AI models predicted optimal antibody structures computationally. CEO Sean McClain emphasized the efficiency gains: "We got to the clinic in roughly half the time, with an order-of-magnitude less cost-$15 million versus $50–100 million traditionally."  </p>
<p>The Phase I trial, involving 40 healthy participants, will assess safety, tolerability, and pharmacokinetics, with interim data expected in late 2025. Notably, ABS-101 is administered subcutaneously (via needle) rather than intravenously, accelerating its path to a patient-friendly final form.  </p>
<h4>Advantages of AI-Driven Drug Design</h4>
<p>Christian Stegmann, Absci’s head of drug development, highlighted ABS-101’s reduced immunogenicity risk-a common hurdle in antibody therapies. "Others have brought antibodies to the clinic with shortcomings, like triggering anti-drug antibodies," he said. AI optimization also enabled a longer half-life, potentially allowing less frequent dosing for IBD patients.  </p>
<p>Beyond ABS-101, Absci’s pipeline includes ABS-201 for alopecia and endometriosis, slated for Phase I trials in early 2026. The company’s stock surged 25% post-announcement, reflecting investor optimism in AI’s role in reshaping drug discovery.  </p>
<h4>The Road Ahead for AI-Designed Therapies</h4>
<p>While no AI-developed drug has yet gained FDA approval, ABS-101’s progress signals a turning point. The FDA’s Center for Drug Evaluation reported over 500 AI-aided applications in 2023, but Absci’s end-to-end AI approach sets it apart. As McClain noted, the goal is to "predict the biology"-designing antibodies that precisely bind targets for desired therapeutic effects.</p>
                </section>

                
                <footer>
                    <div class="tags">
                        Tags: <span id="article-tags"><a href="https://dacoolaa.netlify.app/topic.html?name=Absci%20generative%20AI%20therapy" class="tag-link">Absci generative AI therapy</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=Sean%20McClain%20Absci%20interview" class="tag-link">Sean McClain Absci interview</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=irritable%20bowel%20disease%20AI%20treatment" class="tag-link">irritable bowel disease AI treatment</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=AI-designed%20drug%20trial" class="tag-link">AI-designed drug trial</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=Absci%20ABS-101%20clinical%20trial" class="tag-link">Absci ABS-101 clinical trial</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=FDA%20approval%20for%20AI-designed%20drugs" class="tag-link">FDA approval for AI-designed drugs</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=generative%20AI%20drug%20development" class="tag-link">generative AI drug development</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=AI%20in%20drug%20development%20process" class="tag-link">AI in drug development process</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=AI%20drug%20discovery%20milestones" class="tag-link">AI drug discovery milestones</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=Phase%20I%20trial%20for%20AI-designed%20drug" class="tag-link">Phase I trial for AI-designed drug</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=AI-designed%20drug%20for%20IBD" class="tag-link">AI-designed drug for IBD</a>, <a href="https://dacoolaa.netlify.app/topic.html?name=first%20AI-designed%20drug%20human%20trial" class="tag-link">first AI-designed drug human trial</a></span>
                    </div>
                </footer>
                

            </article>

            <aside class="sidebar latest-news">
                <h2>Latest News</h2>
                <div id="latest-news-content">
                    <!-- JS will populate this list with article cards -->
                    <p class="placeholder">Loading latest news...</p>
                </div>
            </aside>

        </div> <!-- End main-content-grid -->
    </div> <!-- End site-content-wrapper -->

    <!-- GLOBAL FIXED BROWSER TTS PLAYER BUTTON -->
    
    

    <script src="../js/script.js"></script> <!-- Relative path from articles/ to public/js/ -->

</body>
</html>